EDS ECHO Clinicians Australasia (C) Application

EDS ECHO AUSTRALASIA

This is a free program for healthcare professionals worldwide, across all disciplines who want to improve their ability to care for people with EDS, HSD and associated symptoms and conditions.

Please complete the application form below to apply for a place on the EDS ECHO Clinicians Australasia (1C) Program.

EDS ECHO Clinicians Australasia (1C) – Program Details:

The EDS ECHO Clinicians program is a free program for healthcare professionals worldwide, across all disciplines who want to improve their ability to care for people with EDS, HSD, and associated symptoms and conditions.

The programs consist of expert presentations and case-based interactive sessions delivered virtually via the Zoom platform. Each session is 1hr 30 minutes in length and is led by Dr. Fraser Burling.

Participants who are accepted into the program are asked to attend as much of the program as possible to get the most out of their place. All participants are encouraged to share their cases and questions in the sessions and are guided to further educational material and support.

For more information, visit our dedicated EDS ECHO Clinicians web page.

Program: EDS ECHO Clinicians Australasia (1C)
Clinical Lead: Dr. Fraser Burling
Thursdays at:
4:00pm – 5:30pm Singapore (SGT)
6:00pm – 7:30pm Sydney (AEST)
8:00pm – 9:30pm Auckland (NZST)
 Session 1 – Hypermobility – Assessment and Management May 5, 2022
Session 2 – HSD and Hypermobile EDS May 12, 2022
 Session 3 – Rarer Types of EDS and the Differential Diagnosis June 2, 2022
 Session 4 – Cardiovascular Dysautonomia June 16, 2022
 Session 5 – Gastroenterological Disorders in EDS and HSD June 23, 2022
 Session 6 – Role of Osteopathy in Hypermobility July 7, 2022
 Session 7 – Musculoskeletal Therapies in EDS and HSD July 14, 2022
 Session 8 – Open Discussion – Participant Topics July 21, 2022

PLEASE NOTE – Session dates and topics are subject to change.

Please visit https://www.worldtimebuddy.com, or your preferred time zone converter to confirm the correct start time in your location.

The program content is currently only presented in English.

This is a virtual program, you will be sent a link to join the sessions which are run via the zoom platform. Once signed up, we ask that you attend a minimum of 3 out of the 8 sessions. You can catch up with the sessions you miss by watching our password protected recordings online. For all queries regarding EDS ECHO, please email our EDS ECHO Program Coordinator.

Project ECHO® designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Please complete and submit the following information to apply for a place on the program:

The EDS ECHO Clinicians Australasia (1C) Program has now reached full capacity and applications have now closed.

In support of improving patient care, this activity has been planned and implemented by The Ehlers-Danlos Society and Project ECHO®.  Project ECHO® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

EDS ECHO

AMA Designation Statement
Project ECHO® designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.

None of the planners and presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Alan Hakim, MD; Stacey Simmonds; Paul Gardener; Owen Moore; Lara Bloom, Prof; Jane Schubart, MD; Rebecca Bascom, MD; Shani Weber; Fraser Burling, MD;

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company:

Nature of Relationship Name of Ineligible Company
Dr. Clair Francomano Consultant
Advisor

Acer Therapeutics
Scientific Advisory Board, Kyani International

All of the relevant financial relationships listed for this individual have been mitigated.